Transforming Growth Factor α Expression Drives Constitutive Epidermal Growth Factor Receptor Pathway Activation and Sensitivity to Gefitinib (Iressa) in Human Pancreatic Cancer Cell Lines (vol 66, pg 3802, 2006)

被引：0
|
作者：
Nawrocki, S. T.
Carew, J. S.
Pino, M. S.
Highshaw, R. A.
Dunner, K., Jr.
Huang, P.
Abbruzzese, J. L.
McConkey, D. J.
机构：
来源：
CANCER RESEARCH | 2010年 / 70卷 / 02期
关键词：
D O I：
10.1158/0008-5472.CAN-09-4221
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：852 / U1
页数：2
相关论文
共 50 条
  • [1] Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines. (vol 66, pg 3802, 2006)
    Pino, M. S.
    Shrader, M.
    Baker, C. H.
    Cognetti, F.
    Xiong, H. Q.
    Abbruzzese, J. L.
    McConkey, D. J.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12) : 3389 - 3389
  • [2] Transforming growth factor a expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines
    Pino, MS
    Shrader, M
    Baker, CH
    Cognetti, F
    Xiong, HQ
    Abbruzzese, JL
    McConkey, DJ
    CANCER RESEARCH, 2006, 66 (07) : 3802 - 3812
  • [3] Expression of transforming growth factor alpha and epidermal growth factor receptor in human bladder cancer
    Thogersen, VB
    Jorgensen, PE
    Sorensen, BS
    Bross, P
    Orntoft, T
    Wolf, H
    Nexo, E
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1999, 59 (04): : 267 - 277
  • [4] RETRACTION: Epidermal Growth Factor Receptor-Related Protein Inhibits Cell Growth and Invasion in Pancreatic Cancer (Retraction of Vol 66, Pg 7653, 2006)
    Mohammad, R.
    Abbruzzese, J. L.
    Wang, Z.
    Sengupta, R.
    Banerjee, S.
    Li, Y.
    Rahman, K. M. W.
    Aboukameel, A.
    Majumdar, A. P. N.
    Sarkar, F. H.
    Zhang, Y.
    CANCER RESEARCH, 2018, 78 (18) : 5474 - 5474
  • [5] Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer
    Jimeno, Antonio
    Tan, Aik Choon
    Coffa, Jordy
    Rajeshkumar, N. V.
    Kulesza, Peter
    Rubio-Viqueira, Belen
    Wheelhouse, Jenna
    Diosdado, Begona
    Messersmith, Wells A.
    Lacobuzio-Donahue, Christine
    Maitra, Anirban
    Varella-Garcia, Marileila
    Hirsch, Fred R.
    Meijer, Gerrit A.
    Hidalgo, Manuel
    CANCER RESEARCH, 2008, 68 (08) : 2841 - 2849
  • [6] Gefitinib inhibits the growth and invasion of urothelial carcinoma cell lines in which Akt and MAPK activation is dependent on constitutive epidermal growth factor receptor activation
    Nicolle, G
    Daher, A
    Maillé, P
    Vermey, M
    Loric, S
    Bakkar, A
    Wallerand, H
    Vordos, D
    Vacherot, F
    de Medina, SGD
    Abbou, CC
    Van der Kwast, T
    Thiery, JP
    Radvanyi, F
    Chopin, DK
    CLINICAL CANCER RESEARCH, 2006, 12 (09) : 2937 - 2943
  • [7] Expression and localization of epidermal growth factor, transforming growth factor-α and epidermal growth factor receptor in the canine testis (vol 62, pg 59, 2016)
    Tamada, Hiromichi
    Takemoto, Kohei
    Tominaga, Masato
    Kawate, Noritoshi
    Takahashi, Masahiro
    Hatoya, Shingo
    Matsuyama, Satoshi
    Inaba, Toshio
    Sawada, Tsutomu
    JOURNAL OF REPRODUCTION AND DEVELOPMENT, 2016, 62 (02):
  • [8] Modulation of the activity of chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib ('Iressa', ZD1839) in human cancer cell lines.
    Friedmann, BJ
    Caplin, M
    Hartley, JA
    Hochhauser, D
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6094S - 6094S
  • [9] Effects of Gefitinib, an Epidermal Growth Factor Receptor Inhibitor, on Human Placental Cell Growth (vol 122, pg 737, 2013)
    Dimitriadis, Evdokia
    OBSTETRICS AND GYNECOLOGY, 2021, 137 (05): : 962 - 962
  • [10] Formation of Gefitinib-Resistant Lung Cancer Cell Lines and their Changes in Epidermal Growth Factor Receptor Signaling Pathway
    Song, Yunxi
    Ma, Jianxin
    INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 84 (05) : 1269 - 1278
12345